Gan & Lee Pharmaceuticals subsidiary receives GMP certification from the Brazilian National Health Surveillance Agency.

19:21 02/04/2026

Ganli Pharmaceutical (603087.SH) announced that its subsidiary Ganli Pharmaceutical Brazil Trade and Pharmaceutical Import Co., Ltd. (referred to as "Ganli Brazil") recently received the Drug Manufacturing Quality Management Practice (GMP) certification issued by the Brazilian National Health Surveillance Agency (ANVISA). The certification scope includes raw materials for insulin of porcine origin and raw materials for insulin of lantus origin.

Gan & Lee Pharmaceuticals (603087.SH) announced that its subsidiary Gan & Lee Pharmaceuticals Brazil Trade and Pharmaceutical Imports Ltd. (referred to as "Gan Lee Brazil") has received the Good Manufacturing Practice (GMP) certification certificate issued by the Brazilian Health Surveillance Agency (ANVISA). The certification scope includes insulin raw materials and insulin raw materials. The successful passing of ANVISA's GMP certification paves a solid foundation for the company's products, insulin and insulin, to enter the Brazilian market. This is of great significance for advancing the company's internationalization strategy.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.